See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Basketball
Vatican
Wrestling
Baseball
Donald Trump
MLS
Tennis
Hockey
Israel-Hamas Conflict
Elon Musk
Hamas
Published • loading... • Updated

2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

Summary by Macau Business
YANTAI, China, Dec. 13, 2024 /PRNewswire/ — On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session “Novel HER2 Therapeutics” of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. (“RemeGen”) (9995.HK, 688331.SH) presented for the first time the data from a phase III study (RC48-C006, NCT03500380) of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced breast cancer with liver metastasi…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
Macau BusinessMacau Business

2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

YANTAI, China, Dec. 13, 2024 /PRNewswire/ — On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session “Novel HER2 Therapeutics” of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. (“RemeGen”) (9995.HK, 688331.SH) presented for the first time the data from a phase III study (RC48-C006, NCT03500380) of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced breast cancer with liver metastasi…

Read Full Article
vir.com.vnvir.com.vn

Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

YANTAI, China, Dec. 13, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data from a phase III study (RC48-C006, NCT03500380) of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced breast cancer with liver metastas…

Read Full Article
stocktitan.netstocktitan.net

RemeGen's Phase 3 Cancer Drug Shows Breakthrough Results, Doubles Survival Time in HER2+ Breast Cancer Study

RemeGen's Disitamab Vedotin demonstrates groundbreaking efficacy in Phase 3 trial, doubling progression-free survival for HER2+ breast cancer patients with liver metastasis.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Thursday, December 12, 2024.
Sources are mostly out of (0)

Similar News Topics

Yantai

Yantai

News
For You
Search
BlindspotLocal